貝康醫療宣佈為1000個罕見病家庭提供大型公益資助活動,全球首款遺傳病阻斷試劑盒進入臨牀試驗!
格隆匯3月1日丨輔助生殖領域龍頭貝康醫療(2170.HK)日前宣佈了一項針對1000個罕見病家庭的大型公益活動,旨在幫助這些家庭阻斷遺傳病的代代相傳。貝康醫療自主研發了一款針對遺傳病阻斷的胚胎檢測試劑盒產品,該產品能夠通過對多枚胚胎的逐一檢測,從中挑選出不含有致病基因缺陷的胚胎進行移植,徹底阻斷遺傳病,這也是中國第一次掌握解決遺傳病親子代傳遞難題的尖端科技。據悉,貝康醫療已經完成了上述產品的註冊檢驗,正式進入了臨牀試驗階段,預計將於2022年獲得醫療器械註冊證,這也將是全球首個能夠實現遺傳病阻斷的胚胎檢測臨牀註冊產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.